

AMENDMENT TO THE CLAIMS

1. – 32 (Canceled).
33. (New) An N-[[[(piperazinyl)hetaryl]arylsulfonamide compound wherein the compound is N-[6-(4-allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide.
34. (New) A pharmaceutical composition which comprises at least one compound as claimed in claim 33 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I together with physiologically acceptable carriers and/or auxillary substances.
35. (New) A method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor antagonist or a dopamine D3 agonist, the medical disorder selected from the group consisting of Parkinson's disease and schizophrenia, said method comprising administering an effective amount of the compound of claim 30 to a subject in need thereof.